Results 181 to 190 of about 25,852 (227)

Effect of oral care models on the prevention of oral mucositis induced by high-doses of melphalan in patients undergoing ASCT. [PDF]

Medicine (Baltimore)
Wu Q, Zhu X, Liu M.
europepmc   +1 more source

Polymerase theta inhibition impairs tumor growth and amplifies melphalan-induced DNA damage in multiple myeloma. [PDF]

J Transl Med
Li Q, Ma C, Zuo L, Xu A, Zhang B, Zhao F, Liu L, Zhao X, Hu Y, Sun C.   +9 more
europepmc   +1 more source

Long-term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma. [PDF]

In Vivo
Hur JY, Park HS, Choi Y, Park H, Lee YE, Jeong J, Cha S, Choi EJ, Lee JH, Lee YS, Jeon M, Woo JM, Kang YA, Kang H, Lee JH.   +14 more
europepmc   +1 more source

Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023. [PDF]

Oncotarget
Kahlon N, Bansal N, Baddam S, Rajput J, Qureshi Z.   +4 more
europepmc   +1 more source

Cytotoxic Profiling of 3',4',5'-Trimethoxychalcones Reveals Cell-Line-Dependent Cytotoxic Activity: An In Vitro and In Silico Study. [PDF]

Chem Biodivers
Mehandzhiyski AY, Beraich A, Velkov Z, Zaharieva M, Konstantinov S, Batovska D.   +5 more
europepmc   +1 more source

Evolution of outcomes in autologous stem cell transplantation for hodgkin lymphoma over 2 decades at King Hussein cancer center. [PDF]

Ann Hematol
Abdel Rahman Z, Yaseen A, Zayed A, Alkhdour L, Ribie M, Alamoush A, Barakat F, Alrawashdeh M, Abu Fara A, Halahleh K, Shahin O, Al-Ibraheem A, Ma'koseh M.   +12 more
europepmc   +1 more source

Cutaneous plasmacytosis with atypical clinical behavior in two dogs. [PDF]

J Vet Med Sci
Inai K, Shimoyama Y, Teh APP, Chambers JK, Iwasaki T, Kitagawa K.   +5 more
europepmc   +1 more source

The role of antioxidants in multiple myeloma: diagnostic, prognostic, and therapeutic applications: a narrative review. [PDF]

Ther Adv Hematol
Admas S, Teketelew BB, Alemu N, Marelgn L, Gelaw Y.   +4 more
europepmc   +1 more source

Melphalan

Reactions Weekly
Encyclopedia of Toxicology (Fourth Edition), Volume 6.Melphalan (CAS 148-82-3) is an alkylating agent usually indicated for the treatment of selective human neoplastic diseases.
Hernández-Moreno, David, Soler-Rodríguez, Francisco, Oropesa-Jiménez, Ana Lourdes   +2 more
core   +8 more sources

High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation

British Journal of Clinical Pharmacology, 2016
Aim: High dose melphalan (HDM) and autologous stem cell transplantation (ASCT) retains a central role in the treatment of myeloma. The aim of this study was to determine whether HDM exposure (area under the concentration vs.
Christa E Nath, Judith Trotman, Campbell Tiley   +2 more
exaly   +2 more sources